Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Efficacy and Safety Study of Subcutaneous Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)

NCT05814159 is registered in ClinicalTrials.gov with Swedish Orphan Biovitrum as lead sponsor.

NCT NCT05814159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05814159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Efficacy and Safety Study of Subcutaneous Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)
Lead sponsor
Swedish Orphan Biovitrum
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 24, 2022
Completion date
June 24, 2026
Enrollment
15 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

still's disease, adult-onset, still's disease, juvenile onset